IRulya Therapeutics Inc IRLA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
Quince Therapeutics to Participate in September 2026 Investor Conferences
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Trading Information
- Previous Close Price
- $31.67
- Day Range
- $27.10–30.04
- 52-Week Range
- $15.23–906.00
- Bid/Ask
- $28.36 / $30.80
- Shares Outstanding
- 1.02M
- Market Cap
- $29.81M
- Volume/Avg
- 62 / 44,982
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
- Website
- https://www.quincetx.com
Valuation
Metric | IRLA |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IRLA |
|---|---|
Quick Ratio | 14.23 |
Current Ratio | 14.52 |
Interest Coverage | — |
Quick Ratio
IRLA
Profitability
Metric | IRLA |
|---|---|
Return on Assets (Normalized) | −32.22% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,340.89% |
Return on Assets
IRLA
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|X$W?XF | LOCK|WXDS< | $138B | |||
| Moderna Inc MRNA | LOCK|wJy$<% | LOCK|>>> | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|<#?%SB | LOCK|<X!& | $93B | |||
| argenx SE ADR ARGX | LOCK|$trmtDS | LOCK|^?v | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|QVQm?^ | LOCK|!@ | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|CBFf&xZ | LOCK|JTS#j | $30B | |||
| Incyte Corp INCY | LOCK|^K?>%v@ | LOCK|%v | $24B | |||
| BioNTech SE ADR BNTX | LOCK|@%FgC^ | LOCK|Sz | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|v%<^MWf | LOCK|B$@% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|<v$>%Q@ | LOCK|WH | $15B |
United States